Ginkgo Bioworks Holdings Share Holder Equity 2020-2022 | DNA

Ginkgo Bioworks Holdings share holder equity from 2020 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
  • Ginkgo Bioworks Holdings share holder equity for the quarter ending March 31, 2022 was $1.614B, a 32180.96% increase year-over-year.
  • Ginkgo Bioworks Holdings share holder equity for 2021 was $1.567B, a 233.45% increase from 2020.
  • Ginkgo Bioworks Holdings share holder equity for 2020 was $0.47B, a INF% increase from 2019.
  • Ginkgo Bioworks Holdings share holder equity for 2019 was $0B, a NAN% decline from .
Ginkgo Bioworks Holdings Annual Share Holder Equity
(Millions of US $)
2021 $1,567
2020 $470
2019 $0
Ginkgo Bioworks Holdings Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $1,614
2021-12-31 $1,567
2021-09-30 $1,618
2021-06-30 $5
2021-03-31 $5
2020-12-31
2020-09-30 $0
2019-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.561B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00